Empirical Observations Underestimate the Proportion of Human Immunodeficiency Virus Infections Attributable to Sexually Transmitted Diseases in the Mwanza and Rakai Sexually Transmitted Disease Treatment Trials: Simulation Results
- 1 September 2006
- journal article
- research article
- Published by Wolters Kluwer Health in Sexually Transmitted Diseases
- Vol. 33 (9), 536-544
- https://doi.org/10.1097/01.olq.0000204667.11192.71
Abstract
Background and Objectives: Population attributable fractions (PAF) from observational studies may under- or overestimate the contribution of cofactor sexually transmitted disease (STD) to human immunodeficiency virus (HIV) spread. Empirical PAF estimates from the Mwanza and Rakai trials indicated the proportion of HIV infections attributable to STDs was higher in Mwanza than Rakai. Goal of This Study: Estimate the “true” proportion (PAFM) of HIV infections attributable to STDs in the Mwanza and Rakai STD trial populations and explore how the evaluated interventions prevented HIV infections. Study Design: The STDSIM model was used to simulate the 2 populations at the baseline of the trials (with no STD treatment interventions) and counterfactual scenarios in which STD cofactor effects on HIV spread were removed either at the start of the trials or 2, 10, and 20 years into the HIV epidemics. Similar methods were used to quantify the contribution of the cure of each STD to overall HIV impact in each site. Results: In Mwanza, the highest PAFM for the effect of any single STD over the 2 years of the trial was due to chancroid (40%). The PAFM for all curable STD was 65%. In Rakai, herpes simplex virus type 2 (HSV-2) was the most important STD (PAFM = 23%); the PAFM for curable STD was 20%. In both sites, the proportion of new infections due to treatable STD decreased over time. The decrease was greater for Rakai, where a behavioral risk reduction that preceded the trial reduced STD prevalence. In both sites, the importance of HSV-2 increased later in the HIV epidemics and STD increased transmission of HIV more than acquisition of HIV. In the Mwanza trial, treatment of chancroid contributed most to preventing new HIV infections. Conclusions: PAFs calculated from empirical data underestimated the contribution of STD to HIV spread in the Mwanza and Rakai trial populations because STD effects on HIV transmission (as opposed to acquisition) were not captured in the observationally based studies.Keywords
This publication has 33 references indexed in Scilit:
- Syndromic management of sexually-transmitted infections and behaviour change interventions on transmission of HIV-1 in rural Uganda: a community randomised trialThe Lancet, 2003
- Estimating the Magnitude of STD Cofactor Effects on HIV TransmissionSexually Transmitted Diseases, 2001
- Syndromic treatment of sexually transmitted diseases reduces the proportion of incident HIV infections attributable to these diseases in rural TanzaniaAIDS, 2000
- Control of sexually transmitted diseases for HIV-1 prevention: understanding the implications of the Mwanza and Rakai trialsThe Lancet, 2000
- Relative risks and population attributable fraction of incident HIV associated with symptoms of sexually transmitted diseases and treatable symptomatic sexually transmitted diseases in Rakai District, UgandaAIDS, 1999
- Control of sexually transmitted diseases for AIDS prevention in Uganda: a randomised community trialThe Lancet, 1999
- Sexually transmitted diseases enhance HIV transmission: no longer a hypothesisThe Lancet, 1998
- Human Immunodeficiency Virus Transmission and the Role of Other Sexually Transmitted DiseasesSexually Transmitted Diseases, 1996
- Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trialThe Lancet, 1995
- Epidemiological SynergySexually Transmitted Diseases, 1992